| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ani Pharmaceuticals, Inc. (ANIP) has 15 insiders with recent SEC Form 4 filings, including 1 buy and 18 sells. ANIP is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| COO | 431.9K | $35.12M | - | |
| CEO | 411.2K | $33.43M | - | |
| CFO | 230.9K | $18.77M | - | |
| VP | 158.5K | $12.89M | - | |
| Other | 91.3K | $7.42M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 17, 2019 | Marken James G.47 | SVP Ops &Prod Dev | Sell | 8,907 | $70.67 | $629,457.69 | -12.7% | |
| May 15, 2019 | Haughey Thomas | Director | Buy | 2,500 | $69.30 | $173,240.00 | +65.9% | |
| May 15, 2019 | Przybyl Arthur | President And CEO | Sell | 30,000 | $70.07 | $2,102,177.15 | -4.5% | |
| May 14, 2019 | Marken James G.47 | SVP Ops &Prod Dev | Sell | 4,917 | $70.31 | $345,714.27 | -6.6% | |
| May 13, 2019 | Schrepfer Robert W | SVP - New Bus Dev &Spec Sales | Sell | 2,409 | $71.13 | $171,352.17 | -4.1% | |
| Mar 19, 2019 | Przybyl Arthur | President And CEO | Sale+OE | 27,625 | $63.53 | $1,754,959.79 | -6.3% | |
| Mar 13, 2019 | Schrepfer Robert W | SVP - New Bus Dev &Spec Sales | Sale+OE | 11,796 | $64.44 | $760,167.67 | -7.6% | |
| May 16, 2018 | Marshbanks Tracy | Director | Sell | 38,236 | $62.33 | $2,383,192.70 | -3.3% | |
| May 10, 2018 | Marshbanks Tracy | Director | Sell | 62,431 | $62.07 | $3,874,950.62 | -4.8% | |
| Apr 18, 2018 | Marshbanks Tracy | Director | Sell | 33,200 | $62.09 | $2,061,388.00 | -6.9% |